Topic
Formestane
About: Formestane is a research topic. Over the lifetime, 174 publications have been published within this topic receiving 7017 citations. The topic is also known as: CGP-32349 & 4-hydroxy-Δ4-androstenedione.
Papers published on a yearly basis
Papers
TL;DR: A functional in vitro role of DHEA is suggested in activating the ERE in the presence of the classic ER in transiently transfected cells.
47 citations
TL;DR: Formestane 250 mg once bi-weekly seems to be an attractive alternative third-line hormonal therapy for the treatment of patients with MBC, previously treated with nSAI.
45 citations
TL;DR: Although the CR/PR and SD(6m) groups had similar times to treatment failure, patients withCR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.
Abstract: PURPOSE: In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD6m) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD6m). We evaluated the impact of response and/or clinical benefit on quality of life (QL) in postmenopausal patients under second-line endocrine treatment after failure of tamoxifen. PATIENTS AND METHODS: One hundred twenty-eight of 177 eligible patients of a randomized trial (Swiss Group for Clinical Cancer Research 20/90) receiving either formestane (250 mg intramuscularly biweekly) or megestrol acetate (160 mg orally daily) were analyzed. The baseline characteristics (with the exception of site of metastases) were balanced among patients with CR/PR, SD6m, and progressive disease (PD). Patients completed QL indicators at baseline and at 1, 3, 5, 7, 9, and 11 months. Responders were separately...
45 citations
TL;DR: The means to evaluate therapeutic combinations in the laboratory to guide potential trial designs and provide the best chance of success to the patients who enter these clinical trials are suggested.
41 citations
TL;DR: The increase in the plasma IGF-I concentration seen during treatment with MA may be secondary to an increased level of intact IGFBP-3, which could reflect an alteration in IGF availability that contributes to the antitumor effect of MA.
Abstract: The effects of treatment with the aromatase inhibitors aminoglutethimide (AG) and formestane or the synthetic progestin megestrol acetate (MA) on plasma levels of insulin-like growth factor I (IGF-1), IGF-II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status were investigated in 39 patients suffering from advanced breast cancer. Treatment with AG and MA elevated plasma levels of IGF-I by mean values of 27% (n = 15; P < 0.025) and 81% (n = 7; P < 0.025), respectively, whereas treatment with formestane had no effect (n = 13). Treatment with AG increased plasma levels of IGFBP-2, as evaluated by Western blotting (P < 0.01). MA caused a significant reduction in IGFBP-3 protease activity (mean reduction, 69%; P < 0.05). These alterations in plasma IGF-I and IGFBP-3 protease activity were reversed 4 weeks after terminating MA therapy (n = 8; P < 0.025). Taken together, 13 of 15 patients had reduced IGFBP-3 protease activity during treatment with MA compared to the control situation (P < 0.0025). Total ...
41 citations
Related Topics (5)
Performance Metrics
| Year | Papers |
|---|---|
| 2020 | 5 |
| 2019 | 6 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 1 |
| 2015 | 2 |